Dihexa

Dihexa is a synthetic oligopeptide derived from angiotensin IV, developed by researchers at Washington State University led by Dr. Joseph Harding. It was designed to be an orally active, blood-brain barrier permeable compound that activates the hepatocyte growth factor (HGF)/c-Met receptor system in the brain. This system plays critical roles in neuronal development, synapse formation, and cognitive function.

The most remarkable claim about Dihexa is its reported potency: in laboratory assays, it was found to be approximately 10 million times more potent than brain-derived neurotrophic factor (BDNF) at promoting the formation of new synaptic connections (synaptogenesis). This extraordinary potency, documented in the original research paper published in the Journal of Pharmacology and Experimental Therapeutics in 2013, generated enormous excitement in the nootropics and cognitive enhancement communities.

In animal studies, Dihexa demonstrated the ability to restore cognitive function in aged rats with impaired learning and memory. Rats treated with Dihexa showed improved performance in spatial learning tasks (water maze) comparable to young animals. The peptide appeared to work by augmenting HGF/c-Met signaling, promoting the formation of new synaptic connections in brain regions critical for learning and memory, particularly the hippocampus.

Despite its compelling preclinical profile, several important caveats exist. Human clinical trials have not been conducted, so safety and efficacy in humans are unestablished. The HGF/c-Met pathway is also known to play a role in cancer cell proliferation and metastasis, raising theoretical concerns about long-term use. The extraordinary potency claims, while published in peer-reviewed literature, have not been widely replicated by independent groups. Dihexa represents both the exciting potential and the significant uncertainties inherent in cutting-edge neuropeptide research.